* Pathogenesis of CRGV (a thrombotic microangiopathy, or TMA)
* Brief overview of human TMAs and TMAs in other species
* Case presentation (seasonality, clinical signs)
* Diagnostic approach to suspected cases
* Differences between AKI and CKD
* Therapeutic options for azotaemic cases
* Prognosis for azotaemic and non-azotaemic CRGV
* Brief summary of current research
The evening will begin with an introduction to ‘Cutaneous and Renal Glomerular Vasculopathy’ (CRGV) including terminology. The pathogenesis of the illness as a thrombotic microangiopathy (TMA) is covered, followed by a brief history of thrombotic microangiopathies in humans and veterinary species. We will cover the previous reports of CRGV in racing greyhounds from the USA and will then move on to describe the signalment and epidemiology of CRGV cases in the UK. We will touch on previous investigations into the aetiology, followed by a more detailed look at the typical clinical signs, including some photographic examples of the range of skin lesions seen.
This will be followed by covering the approach to suspected cases. Laboratory findings and ways to monitor non-azotaemic, and approach azotaemic, cases will be detailed, followed by a brief refresher about acute kidney injury (AKI) versus chronic kidney disease (CKD).
The management for suspected azotaemic CRGV cases is covered, including how to calculate appropriate fluid therapy in the setting of AKI. Management of oligoanuria, including medical management, and a brief mention of peritoneal dialysis and continuous renal replacement therapy (CRRT) follows on from this.
We will then move on to a comparison between treatment of human TMA illnesses and CRGV. Dermal and renal histopathology findings and prognosis will be discussed. We will finish with a look at current research, and provide further resources and reading, before a final summary of the disease and current knowledge, completes the talk.
* To understand the pathogenesis of CRGV as a thrombotic microangiopathy (abbreviated to TMA). We will include a brief overview of human TMAs and TMAs in other species
* To recognise the common presentation (including seasonality, habitat / geographical locations) and clinical signs associated with CRGV
* To understand the possible risk factors for disease development and be able to advise owners appropriately regarding what is currently known and unknown about prevention
* To understand the diagnostic approach to, and monitoring of, suspected cases
* To recognise the differences between pathogenesis, diagnosis and management of AKI and CKD
* To be able to discuss therapeutic options and advise owners regarding the prognosis for azotaemic and non-azotaemic CRGV
* To be aware of the current research
Laura Holm BVM&S CertSAM MRCVS
RCVS Advanced Practitioner in Small Animal Medicine